Potential biofluid markers and treatment targets for renal cell carcinoma (Q38094918)

28 August 2017

Potential biofluid markers and treatment targets for renal cell carcinoma (English)

1 reference

28 August 2017

Hiromi I Wettersten

1

1 reference

28 August 2017

Robert H Weiss

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

2 April 2013

1 reference

28 August 2017

Nature Reviews Urology

1 reference

28 August 2017

10

1 reference

28 August 2017

336-344

1 reference

28 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2013.52

28 August 2017

0 references

cites work

The epidemiology of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

RCDB: Renal Cancer Gene Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Cancer incidence before and after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Epidemiology and risk factors for kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Urine metabolomics for kidney cancer detection and biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Endogenous kynurenines as targets for drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Grade-dependent proteomics characterization of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

IDO-expressing regulatory dendritic cells in cancer and chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Urinary biomarkers for the early diagnosis of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Pathway signature and cellular differentiation in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Cardiac insulin resistance and microRNA modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Circulating microRNAs as stable blood-based markers for cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Circulating microRNAs in breast cancer and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

VEGF-receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Kidney cancer: identification of novel targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

VHL and HIF signalling in renal cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Roles of histone acetyltransferases and deacetylases in gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

CRM1-mediated nuclear export of proteins and drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Examination of the expanding pathways for the regulation of p21 expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Nuclear export of proteins and drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Evaluation of HIF-1 inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Analysis of PPAR alpha function in human kidney cell line using siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Temsirolimus, an inhibitor of mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

The pattern of excess cancer in dialysis and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

31 March 2020

IDO: more than an enzyme

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Prognostic significance of morphologic parameters in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Vascular endothelial growth factor expression is increased in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Activation of the mTOR signaling pathway in renal clear cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Molecular and therapeutic potential and toxicity of valproic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.52

VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation

31 March 2020

1 reference

12 December 2020

Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy

1 reference

12 December 2020

Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand).

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions

1 reference

12 December 2020

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors

1 reference

12 December 2020

Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury

1 reference

12 December 2020

Radiologic evaluation of hematuria: guidelines from the American College of Radiology's appropriateness criteria.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Molecularly targeted agents for renal cell carcinoma: the next generation.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.52

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference